Cancer Pharmacokinetics and Pharmacodynamics Facility

癌症药代动力学和药效学设施

• 批准号: 10474508
• 负责人: Jan Hendrik Beumer
• 金额: $ 22.4万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-10 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10474508
• 关键词: Adopted; Advisory Committees; Antineoplastic Agents; Award; Biological Assay; Budgets; Cancer Center; Cancer Center Support Grant; Capital; Cells; Clinical; Clinical Pharmacology; Clinical Trials; Clinical Trials Network; Communities; DNA Damage; DNA Markers; Data; Data Analyses; Development; Drug Kinetics; Ensure; Equipment; Exposure to; Freezing; Funding; High Pressure Liquid Chromatography; Human Resources; Hybrids; Injections; Investigation; Ions; Joints; Label; Lead; Liquid substance; Malignant Neoplasms; Measures; Medicine; Methodology; Methods; NCI Center for Cancer Research; Nitrogen; Outcome; Peer Review Grants; Pharmaceutical Preparations; Pharmacodynamics; Pharmacologic Substance; Pharmacology; Phase I Clinical Trials; Phase II Clinical Trials; Philosophy; Population; Power Sources; Procedures; Process; Publications; Quality Control; Reader; Reagent; Research; Research Design; Research Personnel; Resource Sharing; Role; Sampling; Science; Scientist; Scintillation Counter; Services; Site; Specialist; Therapeutic Studies; Training; Translational Research; Validation; Water; absorption; drug development; early phase clinical trial; experience; instrumentation; meetings; member; mid-career faculty; novel; novel anticancer drug; pharmacodynamic biomarker; pharmacokinetics and pharmacodynamics; pre-clinical; professor; programs; sample collection; skills; small molecule

Abstract: Cancer Pharmacokinetics and Pharmacodynamics Facility (CPPF) The Hillman Cancer Center (HCC) Cancer Pharmacokinetics and Pharmacodynamics Facility (CPPF) is an important shared resource that supports science conducted by the HCC research programs and has a major impact on cancer drug development on a national level by providing state-of-the-art and comprehensive quantitative and qualitative bioanalytical support for preclinical and clinical cancer therapeutic studies. The activities of CPPF have earned national recognition for its exceptional service in developing and delivering PK and PD analyses of investigational agents. CPPF: (1) provides extensive pharmacology expertise to investigators by assisting in PK and PD study design and sample collection; (2) develops and provides quality-assured/quality-controlled quantitative and qualitative assay capabilities for rapid and efficient PK and PD bioanalyses; and (3) integrates PK/PD data through sophisticated data analyses. CPPF is located in two contiguous lab spaces with a shared office pod in the HCC Research Pavilion. Major equipment includes 3 Waters QuattroMicro LC-MS/MS, 2 SCIEX4000 LC-MS/MS (1 hybrid linear ion-trap), 2 HPLC-UV/FL/DAD, 1 HPLC-UV/RAD, 1 atomic absorption spectrometer, a LICOR Odyssey infra-red scanner, a Tecan Infinite Microplate Reader, and a Nexcelom Cellometer K2 Cell counter. Ancillary equipment includes -20 °C and -80 °C freezers, a nitrogen generator, and an uninterrupted power supply, as well as access to shared instrumentations including a liquid scintillation counter. CPPF is directed by Drs. Jan Beumer, Professor of Pharmaceutical Sciences and Medicine, and John Schmitz, Associate Professor of Medicine, and is overseen by an HCC Advisory Committee made up of HCC members. Dr. Beumer leads and Dr. Schmitz actively participates in the weekly Merrill Egorin Translational Research meeting, where HCC early drug development projects are discussed by an inter- disciplinary group of basic, translational, and clinical scientists, thereby ensuring appropriate consideration of CPPF’s role in these projects. During this funding period, CPPF analyzed samples for a total of 36 unique investigators and provided support for all 7 HCC research programs. During this funding period, CPPF developed 37 new assays, an average of 22 assays were used per year, and more than 30,000 samples were analyzed (excluding calibrators, quality controls or assay validation samples). CPPF supported 30 peer-reviewed grants and 70 publications, 30 of which were focused on clinical trials, and 19 of which focused on development of novel assay methodologies.

摘要：癌症药代动力学和药效学研究中心（CPPF）